The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

The Impact of FLT3 Inhibitors for the Treatment of AML

Meir Wetzler, MD
Published Online:3:44 PM, Mon May 5, 2014
Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.

Clinical Pearls

  • In CML, initially only imatinib was available in the frontline, but now nilotinib and dasatinib are approved.
  • FLT3 inhibitors did not show significant efficacy in the relapsed/refractory setting of AML, so they were evaluated in the frontline.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.